[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-risk-myelodysplastic-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-risk-myelodysplastic-syndromes":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100641405","phase-3-rhtpo--csa-vs-csa-in-the-treatment-of-lr-mds-with-thrombocytopenia-100641405",false,"NCT07653581","rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia","rhTPO + CsA Versus CsA Alone in the Treatment of Lower-risk MDS With Thrombocytopenia: a Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Confirmed diagnosis of lower-risk MDS;\n3. Platelet ≤ 30×109\u002FL, or \\\u003C 50×109\u002FL and accompanied by bleeding events;\n4. Baseline liver and kidney functions \\\u003C2 ULN;\n5. Signed the informed consent form;\n6. ECOG 0-2;\n\nExclusion Criteria:\n\n1. History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors;\n2. With splenomegaly or myelofibrosis;\n3. Infections or bleeding that cannot be controlled by standard treatment;\n4. Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site;\n5. History of thromboembolic events, heart attack or stroke and current use of anticoagulants;\n6. Previously received cyclosporine (CsA) or ATG within 6 months;\n7. Previously used IL-11, rhTPO or TPO-RA;\n8. Pregnant or lactating women;\n9. Participated in other clinical trials within 3 months.","ALL","18 Years",{"count":19,"type":20},78,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.",[26],"Lower-risk Myelodysplastic Syndromes","NOT_YET_RECRUITING","2026-06-11",{"date":30,"type":31},"2026-06-17","ACTUAL",{"date":33,"type":20},"2026-06",{"date":35,"type":20},"2029-12",{"name":37,"class":38},"Peking Union Medical College Hospital","OTHER"]